Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
3,187
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice

Wan Qina Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaView further author information
,
Jun Zoua Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaView further author information
,
Yongbiao Huanga Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaView further author information
,
Chaofan Liua Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaView further author information
,
Yalin Kanga Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaView further author information
,
Hu Hana Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China;b Department of Oncology, First Affiliated Hospital, Shihezi University, Shihezi, Xinjiang, ChinaView further author information
,
Yang Tanga Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaView further author information
,
Long Lia Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaView further author information
,
Bo Liua Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaView further author information
,
Weiheng Zhaoa Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaView further author information
&
Xianglin Yuana Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 1824631 | Received 12 Feb 2020, Accepted 07 Sep 2020, Published online: 22 Sep 2020

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Gang Wang, Xiaowan Zhou, Zengli Guo, Nan Huang, Juan Li, Yanfang Lv, Lulu Han, Wei Zheng, Dandan Xu, Dafei Chai, Huizhong Li, Liantao Li & Junnian Zheng. (2022) The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β. Cancer Biology & Therapy 23:1, pages 150-162.
Read now
Fabio Perrotta, Vittorio Chino, Valentino Allocca, Vito D’Agnano, Chandra Bortolotto, Andrea Bianco, Angelo Guido Corsico & Giulia Maria Stella. (2022) Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection. Expert Review of Respiratory Medicine 16:10, pages 1043-1055.
Read now

Articles from other publishers (14)

Jie Tan, Qianfei Xue, Xiao Hu & Junling Yang. (2024) Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis. Journal of Translational Medicine 22:1.
Crossref
Wenlong Chen, Yiwen Wang, Haitao Gu, Yi Zhang, Cong Chen, Tingting Yu & Tao Chen. (2023) Molecular characteristics, clinical significance, and immune landscape of extracellular matrix remodeling-associated genes in colorectal cancer. Frontiers in Oncology 13.
Crossref
Lara Closset, Okan Gultekin, Sahar Salehi, Dhifaf Sarhan, Kaisa Lehti & Jordi Gonzalez-Molina. (2023) The extracellular matrix – immune microenvironment crosstalk in cancer therapy: Challenges and opportunities. Matrix Biology 121, pages 217-228.
Crossref
Tiantian Cai, Jiali Jiang, Wendong Yao, Yan Hu, Sisi Kong, Qiaomei Fan, Xingxing Yan, Fanzhu Li & Zheng Shi. (2023) Pirfenidone inhibits stromal collagen deposition and improves intra-tumoral delivery and antitumor efficacy of Pegylated liposomal doxorubicin. Biomedicine & Pharmacotherapy 157, pages 114015.
Crossref
Aimin Jiang, Na Liu, Jingjing Wang, Xiaoqiang Zheng, Mengdi Ren, Wei Zhang & Yu Yao. (2022) The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?. Frontiers in Immunology 13.
Crossref
Ming Yi, Mengke Niu, Yuze Wu, Hong Ge, Dechao Jiao, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu & Kongming Wu. (2022) Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. Journal of Hematology & Oncology 15:1.
Crossref
Jingjing Liu, Liming Cao, Yuanyuan Li, Pengbo Deng, Pinhua Pan, Chengping Hu & Huaping Yang. (2022) Pirfenidone promotes the levels of exosomal miR-200 to down-regulate ZEB1 and represses the epithelial-mesenchymal transition of non-small cell lung cancer cells. Human Cell 35:6, pages 1813-1823.
Crossref
Chengzhi Zhou, Yilin Yang, Xinqing Lin, Nianxin Fang, Likun Chen, Juhong Jiang, Haiyi Deng, Yu Deng, Minghui Wan, Guihuan Qiu, Ni Sun, Di Wu, Xiang Long, Changhao Zhong, Xiaohong Xie, Zhanhong Xie, Ming Liu, Ming Ouyang, Yinyin Qin, Francesco Petrella, Alfonso Fiorelli, Sara Bravaccini, Yuki Kataoka, Satoshi Watanabe, Taichiro Goto, Piergiorgio Solli, Hitoshi Igai, Yuichi Saito, Nikolaos Tsoukalas, Takeo Nakada, Shiyue Li & Rongchang Chen. (2022) Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis. Frontiers in Immunology 13.
Crossref
Shanshan Huang, Yongbiao Huang, Wanling Lin, Lei Wang, Yang Yang, Piao Li, Lei Xiao, Yuan Chen, Qian Chu & Xianglin Yuan. (2022) Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inf--lammasome Activation, and Reversing Gut Microbiota Disorder. Oxidative Medicine and Cellular Longevity 2022, pages 1-17.
Crossref
Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U. Wells & Manuela Funke-Chambour. (2022) Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges. ERJ Open Research 8:2, pages 00115-2022.
Crossref
Linxuan Ying, Mahsa Yazdani, Richard Koya & Ruogang Zhao. (2022) Engineering tumor stromal mechanics for improved T cell therapy. Biochimica et Biophysica Acta (BBA) - General Subjects 1866:4, pages 130095.
Crossref
Helena Branco, Júlio Oliveira, Catarina Antunes, Lúcio L. Santos, Maria Helena Vasconcelos & Cristina P. R. Xavier. (2022) Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin. International Journal of Molecular Sciences 23:7, pages 3631.
Crossref
Ming Yi, Mengke Niu, Jing Zhang, Shiyu Li, Shuangli Zhu, Yongxiang Yan, Ning Li, Pengfei Zhou, Qian Chu & Kongming Wu. (2021) Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. Journal of Hematology & Oncology 14:1.
Crossref
Tania Ray, Terry Ryusaki & Partha S. Ray. (2021) Therapeutically Targeting Cancers That Overexpress FOXC1: A Transcriptional Driver of Cell Plasticity, Partial EMT, and Cancer Metastasis. Frontiers in Oncology 11.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.